This document discusses the development and challenges of HIV vaccines. Over 250 clinical trials have been conducted since the 1980s but an effective vaccine remains elusive due to biological challenges like HIV's ability to mutate. Newer vaccine approaches like mRNA vaccines show promise, with Moderna announcing positive results from a Phase 1 trial of their mRNA HIV vaccine. However, developing a vaccine that provides broad, long-lasting protection against diverse HIV strains and subtypes continues to be hampered by regulatory hurdles and a lack of funding that matches the burden of HIV in developing countries.